A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer

Michael S. Gordon, David Mendelson, Robert Carr, Raymond A. Knight, Rod A. Humerickhouse, Maria Iannone, Alison T. Stopeck

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences